VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
OMCLOmnicell, Inc.
$40.13$1.8B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksOMCLBalance Sheet

Omnicell, Inc. (OMCL) Balance Sheet

26Y historyFree accessUpdated daily

The company has significantly improved its financial stability by reducing total debt from $614.1M in 2023Q4 to $190.6M as of 2026Q1.

OMCL Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00
Total Current Assets722.3M680.07M815.49M927.57M881.81M780.7M829.41M483.24M397.13M367.12M315.41M264.13M283.38M233.78M180.88M279.39M268.49M251.22M225.29M252.18M129.85M85.59M77.77M63.54M48.45M59.96M36.15M
Cash & Short-Term Investments239.22M196.52M381.68M467.97M341.85M359.72M496.17M136.98M67.19M32.42M54.49M82.22M125.89M104.53M62.31M199.87M183.71M169.23M120.44M169.81M60.86M29.54M30.6M33.52M21.48M23.84M11.97M
Cash Only239.22M196.52M369.2M467.97M330.36M349.05M485.93M127.21M67.19M32.42M54.49M82.22M125.89M104.53M62.31M191.76M175.63M169.23M120.44M169.81M60.86M29.54M19.48M24.5M21.4M16.91M9.68M
Short-Term Investments0012.47M011.49M10.66M10.25M9.77M00000008.11M8.07M0000011.12M9.03M85K6.93M2.29M
Accounts Receivable249.8M216.86M256.4M263.89M299.47M240.89M190.12M218.36M196.24M198.81M150.3M107.96M82.76M58.6M55.12M36.9M42.73M45.88M57.98M37.52M36.05M29.46M24.84M17.27M12.34M18.17M11.04M
Days Sales Outstanding70.3966.884.1483.9784.3477.6777.7888.8590.98101.3379.2181.3268.5256.264.0654.8670.1378.4684.0264.2785.0588.4873.1761.7151.3876.359.8
Inventory99.2M100.91M88.66M110.1M147.55M119.92M96.3M108.01M100.87M96.14M69.3M46.59M31.55M31.46M26.9M18.11M9.79M9.58M12.96M13.73M15.72M13.76M14.59M8.78M12.74M12.7M10.41M
Days Inventory Outstanding54.4954.0550.4762.0976.1875.8173.3985.6888.7289.0466.7771.8755.6364.868.4460.2234.1832.3138.3850.2482.9592.16102.3675.5127.7141.49143.02
Other Current Assets134.08M132.08M61.48M51.36M64.17M31.01M20.7M1.06M12.14M4.5M12.67M7.77M19.66M20.31M21.03M16.46M16.44M16.35M24.3M21.64M9.18M10.29M02.74M000
Total Non-Current Assets1.28B1.29B1.31B1.3B1.33B1.36B995.09M757.57M684.11M613.18M619.7M314.62M276.83M258.72M262.85M82.57M74.81M70.12M83.8M76.24M24.78M14.84M21.73M20.93M17.1M12.15M7.76M
Property, Plant & Equipment144.45M144.48M138.3M133.59M132.01M119.69M114.19M110.38M51.5M42.59M42.01M32.31M36.18M35.25M34.26M17.31M14.35M13.21M16.18M10.18M5.23M4.73M5.66M4.83M5.03M5.38M4.91M
Fixed Asset Turnover8.42x8.20x8.04x8.59x9.82x9.46x7.81x8.13x15.29x16.81x16.49x15.00x12.19x10.80x9.17x14.19x15.50x16.16x15.57x20.92x29.60x25.71x21.90x21.13x17.45x16.14x13.71x
Goodwill737.29M737.95M734.73M735.81M734.27M738.9M499.31M336.54M335.89M337.75M327.72M147.91M122.72M111.34M113.4M28.54M28.54M24.98M24.98M23.08M4.92M3.13M00000
Intangible Assets165.43M170.1M246.7M277.83M323.67M374.61M262.24M209.94M143.69M168.11M190.28M89.67M82.67M81.6M85.16M4.23M4.67M4.23M6.71M9.47M1.07M4.18M5.81M6.32M000
Long-Term Investments227.22M60.74M52.74M54.8M32.92M18.39M22.16M19.75M17.08M15.44M20.59M14.48M10.85M11.48M13.23M8.79M9.22M8.71M10.61M00000000
Other Non-Current Assets122.36M123.04M75.53M64.37M83.74M94.32M82.18M66.83M120.76M39.84M35.05M27.89M23.27M17.94M15.78M9.72M8.37M9.32M8.9M20.63M13.56M4.48M10.26M9.77M12.07M6.77M2.85M
Total Assets2B1.97B2.12B2.23B2.21B2.14B1.82B1.24B1.08B980.3M935.1M578.75M560.21M492.5M443.73M361.97M343.3M321.34M309.09M328.42M154.63M100.43M99.49M84.47M65.54M72.11M43.91M
Asset Turnover0.61x0.60x0.52x0.52x0.59x0.53x0.49x0.72x0.73x0.73x0.74x0.84x0.79x0.77x0.71x0.68x0.65x0.66x0.81x0.65x1.00x1.21x1.25x1.21x1.34x1.21x1.53x
Asset Growth %-35.53%-6.89%-4.76%0.73%3.19%17.43%47.04%14.76%10.3%4.83%61.57%3.31%13.75%10.99%22.59%5.44%6.84%3.96%-5.89%112.39%53.97%0.94%17.79%28.87%-9.11%64.25%-
Total Current Liabilities483.05M476.61M595.68M367.79M428.45M876.16M276.42M237M204.58M212.54M180.91M124.63M112.33M93.07M84.98M58.75M57.96M57.63M57.6M57.82M53.56M33.78M42.05M44.14M48.47M52.15M49.6M
Accounts Payable58.34M43.99M51.78M45.03M63.39M71.51M40.31M46.38M38.04M48.29M27.07M22.65M19.43M16.47M18.25M11M13.24M10.31M9.38M10.12M8.79M4.06M4.49M2.92M5.97M4.84M4.42M
Days Payables Outstanding29.9623.5629.4825.3932.7345.2130.7236.7933.4644.7326.0834.9334.2633.9346.4436.5846.2634.7827.7737.0146.3827.1831.4925.1159.8853.8860.65
Short-Term Debt011.96M174.32M00488.15M00015.21M8.41M000000000000305K1.2M037K
Deferred Revenue (Current)784.44M171.86M201.98M132.28M187.21M152.11M125.2M94.9M81.83M86.1M87.52M53.66M53.73M42.58M41.22M33.4M28.51M14.46M12.08M11.26M7.71M14.51M13.92M12.65M11.6M32.8M3.23M
Other Current Liabilities212.82M191.63M0126.02M73.45M71.13M55.75M44.16M124.88M114.47M118.71M30.13M19.3M13.75M11.43M5.45M7.73M016.01M15.26M10.22M2.55M10.72M12.86M18.01M24.79M25.85M
Current Ratio1.50x1.43x1.37x2.52x2.06x0.89x3.00x2.04x1.94x1.73x1.74x2.12x2.52x2.51x2.13x4.76x4.63x4.36x3.91x4.36x2.42x2.53x1.85x1.44x1.00x1.15x0.73x
Quick Ratio1.29x1.22x1.22x2.22x1.71x0.75x2.65x1.58x1.45x1.28x1.36x1.75x2.24x2.17x1.81x4.45x4.46x4.19x3.69x4.12x2.13x2.13x1.50x1.24x0.74x0.91x0.52x
Cash Conversion Cycle94.9397.29105.13120.67127.8108.28120.45137.74146.24145.64119.89118.2689.8987.0786.0678.4958.057694.6277.5121.62153.46144.04112.1119.19163.91142.17
Total Non-Current Liabilities264.43M266.3M281.97M670.13M652.17M119.65M580.58M158.56M197.04M250.57M322.58M51.73M57.79M51.1M51.16M20.3M19.85M21.41M17.94M15.96M11.08M11.41M3.74M5.57M763K363K19.33M
Long-Term Debt190.56M167.6M166.4M569.66M566.57M0467.2M50M135.42M194.92M245.73M00000000001.29M3.22M0305K363K8.38M
Capital Lease Obligations105.81M24.79M31.12M33.91M39.41M39.91M48.9M50.67M0000000000000000000
Deferred Tax Liabilities3.9M683K1.11M1.62M2.1M51.7M39.63M39.09M41.48M28.58M51.59M21.82M30.45M28.16M26.4M11.68M9.57M9.67M15.89M12.88M0-9.87M00000
Other Non-Current Liabilities10.16M9.97M7.22M6.32M6.72M7.84M19.17M11.72M9.56M9.83M8.21M11.93M7.02M5.17M30.31M1.34M675K595K1.15M237K995K250K517K5.57M458K010.96M
Total Liabilities747.48M742.91M877.65M1.04B1.08B995.81M857M395.56M401.63M463.11M503.5M176.36M170.12M144.17M136.15M79.05M77.81M79.03M75.53M73.78M64.63M45.19M45.79M49.71M49.24M52.51M68.93M
Total Debt190.56M204.34M382.55M614.09M616.74M541.01M528.29M110.73M135.42M210.13M254.14M000000000011.16M3.22M305K1.5M363K8.41M
Net Debt-48.66M7.83M13.35M146.12M286.38M191.96M42.37M-16.48M68.22M177.7M199.65M-82.22M-125.89M-104.53M-62.31M-191.76M-175.63M-169.23M-120.44M-169.81M-60.86M-18.38M-16.26M-24.19M-19.9M-16.55M-1.27M
Debt / Equity0.15x0.17x0.31x0.52x0.55x0.47x0.55x0.13x0.20x0.41x0.59x----------0.20x0.06x0.01x0.09x0.02x-
Debt / EBITDA1.72x2.43x4.25x8.06x6.37x3.10x4.93x0.78x1.41x3.67x3.92x----------7.47x0.22x0.03x-0.11x-
Net Debt / EBITDA-0.44x0.09x0.15x1.92x2.96x1.10x0.40x-0.12x0.71x3.10x3.08x-1.11x-1.80x-1.95x-1.54x-7.92x-9.68x-16.76x-4.58x-7.44x-4.69x-12.30x-1.11x-2.31x--5.03x-
Interest Coverage18.41x2.84x0.07x--17.87x4.00x16.94x13.50x---18.92x45.95x289.34x935.38x260.50x2490.25x80.47x1382.47x--------
Total Equity1.26B1.23B1.24B1.19B1.13B1.15B967.5M845.25M679.62M517.2M431.61M402.39M390.1M348.33M307.58M282.91M265.49M242.3M233.56M254.64M90M55.24M53.7M34.76M16.31M19.6M-25.02M
Equity Growth %3.25%-0.92%4.57%5.2%-1.44%18.52%14.46%24.37%31.4%19.83%7.26%3.15%11.99%13.25%8.72%6.56%9.57%3.75%-8.28%182.94%62.92%2.87%54.49%113.16%-16.81%178.33%-
Book Value per Share27.3526.5726.8826.3024.6323.9222.1219.6816.7613.3611.7110.9610.659.748.998.307.927.567.057.533.112.131.941.370.751.90-14.69
Total Shareholders' Equity1.26B1.23B1.24B1.19B1.13B1.15B967.5M845.25M679.62M517.2M431.61M402.39M390.1M348.33M307.58M282.91M265.49M242.3M233.56M254.64M90M55.24M53.7M34.76M16.31M19.6M-25.02M
Common Stock058K57K56K55K54K53K51K50K48K46K45K43K41K39K38K37K36K35K35K28K26K26K24K22K22K11.73M
Retained Earnings0384.94M382.89M370.36M390.73M368.57M290.72M258.79M197.45M122.58M100.4M99.79M69.03M38.52M14.54M-1.64M-12.03M-16.92M-17.37M-30.09M-72.8M-83.17M-81.09M-91.69M-99M-93.96M-92.8M
Treasury Stock0-368.31M-290.32M-290.32M-290.32M-238.11M-238.11M-185.07M-185.07M-185.07M-185.07M-185.07M-135.05M-110.96M-90M-77.64M-65.06M-65.06M-65.06M00000000
Accumulated OCI0-8.85M-17.2M-13.43M-17.09M-8.41M-5.52M-9.45M-10.85M-6.11M-9.52M-2.73M-1.36M171K131K1K0000012K-33K-19K-4.67M-5.22M-6.35M
Minority Interest000000000000000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Hospital CAPEX budget sensitivity

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Deleveraging Amidst Capital Structure Shifts

According to reported financial statements, Omnicell has successfully reduced its total debt from $614.1M in 2023Q4 to $190.6M by 2026Q1, signaling a deliberate effort to strengthen the balance sheet despite the ongoing transition toward a subscription-based revenue model that creates short-term top-line volatility.

The significant reduction in debt levels suggests management is prioritizing financial flexibility as the company navigates a challenging hospital capital expenditure environment. This deleveraging trend appears to be a strategic response to the high-interest-rate climate, which previously necessitated a more conservative approach to capital structure.

Strategic Debt Reduction Enhances Stability

Based on the provided quarterly data, the company's debt-to-equity ratio has improved from 0.52 in 2024Q1 to 0.15 in 2026Q1, indicating that Omnicell has significantly lowered its financial leverage and reduced the interest burden on its constrained operating cash flows.

The rapid paydown of debt suggests that the company is attempting to insulate itself from the cyclicality of hospital spending by minimizing fixed financial obligations. Investors should monitor whether this lower leverage profile provides sufficient cushion if the transition to recurring revenue models continues to pressure near-term profitability.

Goodwill Concentration Risks Asset Quality

As reported in recent filings, goodwill remains a substantial component of the asset base at $737.3M as of 2026Q1, representing a significant portion of the $2.0B total assets and highlighting potential impairment risks if the acquired pharmacy automation businesses fail to meet growth expectations.

The high concentration of intangible assets relative to tangible property, plant, and equipment suggests that the company's value is heavily tied to past acquisitions rather than physical infrastructure. This asset mix warrants further investigation into the long-term performance of the acquired units, as any shortfall could necessitate non-cash write-downs that would impact equity.

Liquidity Buffers Remain Sufficiently Maintained

Based on the latest 2026Q1 figures, Omnicell maintains a current ratio of 1.50, which, while lower than the 2.52 peak observed in 2023Q4, suggests the company retains an adequate buffer to meet short-term obligations despite the ongoing volatility in its working capital and cash conversion cycles.

The current liquidity position appears stable, though the fluctuation in the current ratio over the last ten quarters reflects the lumpy nature of large-scale hardware installations and associated revenue recognition. The company's ability to manage its cash runway while simultaneously reducing debt indicates a disciplined approach to liquidity management in a period of business model transition.

OMCL — Frequently Asked Questions

Quick answers to the most common questions about buying OMCL stock.

What are the total assets of Omnicell, Inc. (OMCL)?

As of 2025, Omnicell, Inc. (OMCL) had total assets of $1.97B including $680.1M in current assets.

How much debt does Omnicell, Inc. (OMCL) have?

Omnicell, Inc. (OMCL) carries total debt of $204.3M, offset by $196.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Omnicell, Inc.?

Omnicell, Inc. (OMCL) has total shareholders' equity (book value) of $1.23B ($26.57 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Omnicell, Inc.'s current ratio and liquidity?

Omnicell, Inc. (OMCL) reported a current ratio of 1.43x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.